# Primary Gastric Adenocarcinoma with Thyroid Transcription Factor-1 Positivity Mimicking Gastric Metastasis from Lung Cancer: A Case Report

**Authors:** Yoshihito Iijima, Masahito Ishikawa, Shun Iwai, Akihiro Shioya, Nozomu Motono, Sohsuke Yamada, Hidetaka Uramoto

PMC · DOI: 10.70352/scrj.cr.25-0677 · Surgical Case Reports · 2026-01-31

## TL;DR

A rare case of TTF-1-positive primary gastric cancer was initially misdiagnosed as a metastasis from lung cancer, highlighting the need for careful evaluation of such tumors.

## Contribution

This case report demonstrates that TTF-1 positivity in gastric tumors can lead to misdiagnosis and emphasizes the importance of integrating clinical and histological data for accurate diagnosis.

## Key findings

- TTF-1–positive gastric adenocarcinoma was initially misdiagnosed as metastasis from lung cancer.
- Comprehensive evaluation revealed the gastric tumor was primary, not metastatic.
- The patient remained in complete response after surgery and continued treatment.

## Abstract

Thyroid transcription factor-1 (TTF-1) is a well-established immunohistochemical marker for tumors of lung and thyroid origin. Metastatic adenocarcinomas are often tested for TTF-1 expression to identify their primary site. Herein, we report a rare case of TTF-1–positive primary gastric adenocarcinoma that was initially misdiagnosed and treated as postoperative gastric metastasis from primary lung cancer.

A 58-year-old man underwent thoracoscopic right upper lobectomy with systemic lymph node dissection for lung cancer of the right upper lobe. The pathological diagnosis was invasive adenocarcinoma (pT2bN0M0, Stage IIA). He received 3 courses of postoperative adjuvant platinum doublet chemotherapy. One year and 2 months after surgery, he was diagnosed with gastric and adrenal tumors. Immunohistochemical analysis of the gastric lesion demonstrated TTF-1 positivity, leading to the diagnosis of gastric and adrenal metastatic recurrence of lung cancer. The patient received triple therapy with carboplatin, pemetrexed, and pembrolizumab, followed by maintenance therapy with pemetrexed and pembrolizumab. During treatment, the adrenal metastasis achieved a complete response; however, the gastric lesion showed gradual progression on endoscopic follow-up. As primary gastric cancer could not be ruled out, the patient underwent robot-assisted distal gastrectomy with D2 lymph node dissection and Billroth I reconstruction, 3 years and 4 months following lung resection. Immunohistochemical staining of the gastric tumor revealed adenocarcinoma that was positive for TTF-1 and caudal-related homeodomain protein 2 (CDX2) and negative for napsin A. In contrast, lung cancer tissue was weakly positive for TTF-1 and negative for napsin A and CDX2. Based on the immunohistochemical staining and histological findings, the final diagnosis was primary gastric adenocarcinoma. The postoperative course was uneventful, and maintenance chemotherapy with pemetrexed and pembrolizumab was resumed. Four years and 10 months after cancer surgery, the patient remains in complete response.

This case highlights the diagnostic challenge posed by TTF-1–positive gastric tumors, which may be mistaken for metastatic lesions from lung cancer. As TTF-1 expression is not entirely specific to tissues of lung or thyroid origin, diagnosis should be based on a comprehensive evaluation of morphological and immunohistochemical findings, together with clinical information, including treatment response and disease course.

## Linked entities

- **Proteins:** TTF1 (transcription termination factor 1), CDX2 (caudal type homeobox 2), Napsa (napsin A aspartic peptidase)
- **Chemicals:** carboplatin (PubChem CID 426756), pemetrexed (PubChem CID 135410875)
- **Diseases:** adenocarcinoma (MONDO:0004970), lung cancer (MONDO:0005138), gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** NAPSA (napsin A aspartic peptidase) [NCBI Gene 9476] {aka KAP, Kdap, NAP1, NAPA, NR1H2-AS1, SNAPA}, CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}, NKX2-1 (NK2 homeobox 1) [NCBI Gene 7080] {aka BCH, BHC, NK-2, NKX2.1, NKX2A, NMTC1}
- **Diseases:** tumors of lung and thyroid origin (MESH:C567034), gastric and adrenal (MESH:D013272), Gastric Metastasis (MESH:D009362), Metastatic adenocarcinomas (MESH:D000230), Gastric Adenocarcinoma (MESH:D013274), cancer (MESH:D009369), Lung Cancer (MESH:D008175)
- **Chemicals:** pemetrexed (MESH:D000068437), carboplatin (MESH:D016190), platinum (MESH:D010984), pembrolizumab (MESH:C582435)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12863940/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12863940/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12863940/full.md

---
Source: https://tomesphere.com/paper/PMC12863940